0.78 USD
0 (0%)
Taking everything into account, ERYP scores 2 out of 10 in our fundamental rating. ERYP was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of ERYP have multiple concerns. While showing a medium growth rate, ERYP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year ERYP has reported negative net income.
- In the past year ERYP has reported a negative cash flow from operations.
1.2 Ratios
- ERYP has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ERYP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ERYP remains at a similar level compared to 1 year ago.
- ERYP has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -2.54, we must say that ERYP is in the distress zone and has some risk of bankruptcy.
- ERYP's Altman-Z score of -2.54 is in line compared to the rest of the industry. ERYP outperforms 45.57% of its industry peers.
- A Debt/Equity ratio of 0.44 indicates that ERYP is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.44, ERYP is not doing good in the industry: 71.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.54 |
ROIC/WACCN/A
WACC4.93%
2.3 Liquidity
- ERYP has a Current Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
- ERYP has a worse Current ratio (3.65) than 61.67% of its industry peers.
- ERYP has a Quick Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.65, ERYP is doing worse than 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 99.68% over the past year.
- ERYP shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.04%.
- ERYP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.60% yearly.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%
3.2 Future
- ERYP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.28% yearly.
- The Revenue is expected to decrease by -44.77% on average over the next years. This is quite bad
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- ERYP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ERYP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ERYP's earnings are expected to grow with 26.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.28%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ERYP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ERYTECH PHARMA - SPON ADR / ERYP FAQ
What is the ChartMill fundamental rating of ERYTECH PHARMA - SPON ADR (ERYP) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ERYP.
What is the valuation status for ERYP stock?
ChartMill assigns a valuation rating of 2 / 10 to ERYTECH PHARMA - SPON ADR (ERYP). This can be considered as Overvalued.
Can you provide the profitability details for ERYTECH PHARMA - SPON ADR?
ERYTECH PHARMA - SPON ADR (ERYP) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for ERYP stock?
The Earnings per Share (EPS) of ERYTECH PHARMA - SPON ADR (ERYP) is expected to grow by 22.35% in the next year.